The role of neural stem cells for in vitro models of schizophrenia: Neuroprotection via Akt/ERK signal regulation

Schizophrenia Research

Volumn 122, Issue 1-3, 2010, Pages 239-247

  Ono, Takafumi ^a   Hashimoto, Eri ^a   Ukai, Wataru ^a   Ishii, Takao ^b   Saito, Toshikazu ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Atypical antipsychotic; Neural stem cell; Neuroprotection; Schizophrenia

Indexed keywords

DIZOCILPINE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CONTACT; CELL SURVIVAL; CONTROLLED STUDY; NERVE CELL CULTURE; NEURAL STEM CELL; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; BENZODIAZEPINES; BUTADIENES; CELLS, CULTURED; CEREBRAL CORTEX; CHROMONES; CULTURE MEDIA, SERUM-FREE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MICROTUBULE-ASSOCIATED PROTEINS; MORPHOLINES; NEURAL STEM CELLS; NEURONS; NEUROPROTECTIVE AGENTS; NITRILES; ONCOGENE PROTEIN V-AKT; PREGNANCY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 77956183056     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.05.008     Document Type: Article

References (49)

1. Arguello P.A., Gogos J.A. A signaling pathway AKTing up in schizophrenia. J. Clin. Invest. 2008, 118:2018-2021.
2. Beaulieu J.M., Sotnikova T.D., Gainetdinov R.R., Caron M.G. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 2006, 281:32072-32080.
3. Blin O. A comparative review of new antipsychotics. Can. J. Psychiatry 1999, 44:235-244.
4. Buckley P.F. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J. Clin. Pharmacol. 1997, 37:363-378.
5. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
6. Chakos M.H., Schobel S.A., Gu H., Gerig G., Bradford D., Charles C., Lieberman J.A. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Br. J. Psychiatry 2005, 186:26-31.
7. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
8. Dickerson J., Sharp F.R. Atypical antipsychotics and a Src kinase inhibitor (PPI) prevent cortical injury produced by the psychomimetic, noncompetitive NMDA receptor antagonist MK-801. Neuropsychopharmacology 2006, 31:1420-1430.
9. Frankfurt O.S., Krishan A. Identification of apoptotic cells by formamide-induced dna denaturation in condensed chromatin. J. Histochem. Cytochem. 2001, 49:369-378.
10. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 2004, 29:1063-1069.
11. Hayashi H., Tsuchiya Y., Nakayama K., Satoh T., Nishida E. Down-reguration of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling. Genes Cells 2008, 13:941-947.
12. Hetman M., Kanning K., Cavanaugh J.E., Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J. Biol. Chem. 1999, 274:22569-22580.
13. Hunsberger J., Austin D.R., Henter I.D., Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci. 2009, 11:333-348.
14. Inta D., Alfonso J., von Engelhardt J., Kreuzberg M.M., Meyer A.H., van Hooft J.A., Monyer H. Neurogenesis and widespread forebrain migration of distinct GABAergic neurons from the postnatal subventricular zone. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20994-20999.
15. Ishii T., Hashimoto E., Ukai W., Tateno M., Yoshinaga T., Saito S., Sohma H., Saito T. Lithium-induced suppression of transcription repressor NRSF/REST: effects on the dysfunction of neuronal differentiation by ethanol. Eur. J. Pharmacol. 2008, 593:36-43.
16. Jarskog L.F., Selinger E.S., Lieberman J.A., Gilmore J.H. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry 2004, 161:109-115.
17. Johnstone E.C., Frith C.D. Validation of three dimentions of schizophrenic symptoms in a large unselected sample of patients. Psychol. Med. 1996, 26:669-679.
18. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615-675.
19. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
20. Kurosawa S., Hashimoto E., Ukai W., Toki S., Saito S., Saito T. Olanzapine potentiates neural survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins. J. Neural Transm. 2007, 114:1121-1128.
21. Lahti A.C., Weiler M.A., Tamara, Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
22. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 1998, 172:110-120.
23. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999, 46:729-739.
24. Lieberman J.A. Schizophrenia: comments on genes, development, risk factors, phonotype, and course. Biol. Psychiatry 1999, 46:869-870.
25. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62:361-370.
26. Lieberman J.A., Malaspina D., Jarskog L.F. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. CNS Spectr. 2006, 11:1-13.
27. Lieberman J.A., Perkins D.O., Jarskog L.F. Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. CNS Spectr. 2007, 3(Suppl. 4):1-13. quiz 14.
28. Lu X.H., Bradley R.J., Dwyer D.S. Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38. Brain Res. 2004, 1011:58-68.
29. Massana G., Salgado-Pineda P., Junque C., Perez M., Baeza I., Pons A., Massana J., Navarro V., Blanch J., Morer A., Mercader J.M., Bernardo M. Volume changes in gray matter in first-episode neuroleptic-naive schizophrenic patients treated with risperidone. J. Clin. Psychopharmacol. 2005, 25:111-117.
30. McCarley R.W., Wible C.G., Frumin M., Hirayasu Y., Levitt J.J., Fischer I.A., Shenton M.E. MRI anatomy of schizophrenia. Biol. Psychiatry 1999, 45:1099-1119.
31. Newton S.S., Duman R.S. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007, 21:715-725.
32. Nishida E., Gotoh Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem. Sci. 1993, 18:128-131.
33. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52:998-1007.
34. Roitberg B. Transplantation for stroke. Neurol. Res. 2004, 26:256-264.
35. Seo M.S., Kim S.H., Ahn Y.M., Kim Y., Jeon W.J., Yoon S.C., Roh M.S., Juhnn Y.S., Kim Y.S. The effects of repeated administrations of MK-801 on ERK and GSK-3beta signalling pathways in the rat frontal cortex. Int. J. Neuropsychopharmacol. 2007, 10:359-368.
36. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49:1-52.
37. Szeszko P.R., Strous R.D., Goldman R.S., Ashtari M., Knuth K.H., Lieberman J.A., Bilder R.M. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. Am. J. Psychiatry 2002, 159:217-226.
38. Tateno M., Ukai W., Ozawa H., Yamamoto M., Toki S., Ikeda H., Saito S. Ethanol inhibition of neural stem cell differentiation is reduced by neurotrophic factors. Alcohol Clin. Exp. Res. 2004, 28:134S-138S.
39. Tateno M., Ukai W., Yamamoto M., Hashimoto E., Ikeda H., Saito T. The effect of ethanol on cell fate determination of neural stem cells. Alcohol Clin. Exp. Res. 2005, 29:225S-229S.
40. Tateno M., Ukai W., Hashimoto E., Ikeda H., Saito T. Implication of increased NRSF/REST binding activity in the mechanism of ethanol inhibition of neuronal differentiation. J. Neural Transm. 2006, 113:283-293.
41. Toni N., Laplagne D.A., Zhao C., Lombardi G., Ribak C.E., Gage F.H., Schinder A.F. Neurons born in the adult dentate gyrus form functional synapses with target cells. Nat. Neurosci. 2008, 11:901-907.
42. Toro C.T., Deakin J.F. Adult neurogenesis and schizophrenia: a window on abnormal early brain development?. Schizophr. Res. 2007, 90:1-14.
43. Ukai W., Ozawa H., Tateno M., Hashimoto E., Saito T. Neurotoxic potential of haloperidol in comparison with risperidone: implication of Akt-mediated signal changes by haloperidol. J. Neural Transm. 2004, 111:667-681.
44. Wakade C.G., Mahadik S.P., Waller J.L., Chiu F.C. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. 2002, 69:72-79.
45. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29:1230-1238.
46. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 1987, 44:660-669.
47. Yoshinaga T., Hashimoto E., Ukai W., Toki S., Saito S., Saito T. Neural stem cell transplantation in a model of fetal alcohol effects. J. Neural Transm. Suppl. 2007, 72:331-337.
48. Yulug B., Yildiz A., Hudaoglu O., Kilic E., Cam E., Schabitz W.R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res. Bull. 2006, 71:296-300.
49. Zhang L., Zhou R., Xiang G. Stepholidine protects against H2O2 neurotoxicity in rat cortical neurons by activation of Akt. Neurosci. Lett. 2005, 383:328-332.